NASDAQ:SELB - Selecta Biosciences Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.25 +0.09 (+4.17 %) (As of 04/24/2019 06:00 AM ET)Previous Close$2.16Today's Range$2.13 - $2.2952-Week Range$1.41 - $16.55Volume256,248 shsAverage Volume624,207 shsMarket Capitalization$100.65 millionP/E RatioN/ADividend YieldN/ABeta1.6 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses. The company's lead product is SEL-212 that in Phase II clinical trials for the treatment of chronic refractory gout. It is also developing SEL-403, which is in Phase I clinical trials for the treatment of patients with malignant pleural or peritoneal mesothelioma. In addition, the company engages in the development of gene therapy product candidates that are in preclinical development for rare inborn errors of metabolism, including SEL-302, a therapy program for the treatment methylmalonic academia; and SEL-313, a product candidate to treat ornithine transcarbamylase deficiency. Selecta Biosciences, Inc. has license and collaboration agreements with Spark Therapeutics, Massachusetts Institute of Technology, Shenyang Sunshine Pharmaceutical Co., Ltd., and BIND Therapeutics, Inc. The company was founded in 2007 and is headquartered in Watertown, Massachusetts. Receive SELB News and Ratings via Email Sign-up to receive the latest news and ratings for SELB and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SELB Previous Symbol CUSIPN/A CIK1453687 Webwww.selectabio.com Phone617-923-1400Debt Debt-to-Equity RatioN/A Current Ratio1.20 Quick Ratio1.20Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$900,000.00 Price / Sales111.83 Cash FlowN/A Price / Cash FlowN/A Book Value($0.24) per share Price / Book-9.38Profitability EPS (Most Recent Fiscal Year)($2.92) Net Income$-65,340,000.00 Net MarginsN/A Return on Equity-371.11% Return on Assets-97.46%Miscellaneous Employees39 Outstanding Shares44,733,000Market Cap$100.65 million Next Earnings Date5/8/2019 (Estimated) OptionableOptionable Selecta Biosciences (NASDAQ:SELB) Frequently Asked Questions What is Selecta Biosciences' stock symbol? Selecta Biosciences trades on the NASDAQ under the ticker symbol "SELB." How were Selecta Biosciences' earnings last quarter? Selecta Biosciences Inc (NASDAQ:SELB) issued its quarterly earnings results on Friday, March, 15th. The company reported ($0.65) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.10. The firm had revenue of $0.90 million for the quarter. View Selecta Biosciences' Earnings History. When is Selecta Biosciences' next earnings date? Selecta Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, May 8th 2019. View Earnings Estimates for Selecta Biosciences. What price target have analysts set for SELB? 6 equities research analysts have issued 12-month target prices for Selecta Biosciences' shares. Their forecasts range from $4.00 to $33.00. On average, they expect Selecta Biosciences' share price to reach $12.50 in the next year. This suggests a possible upside of 455.6% from the stock's current price. View Analyst Price Targets for Selecta Biosciences. What is the consensus analysts' recommendation for Selecta Biosciences? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Selecta Biosciences in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Selecta Biosciences. What are Wall Street analysts saying about Selecta Biosciences stock? Here are some recent quotes from research analysts about Selecta Biosciences stock: 1. Stifel Nicolaus analysts commented, "We are reiterating our Buy rating and $7 target price after SELB reported its 4Q18 financial and business update. While we believe SELB’s 1Q19 capital raise addressed some of the near-term headwinds for the stock and should allow the company to further develop its lead program, SEL-212, as a treatment for chronic severe gout, we do think the company must execute well in order to achieve its communicated timelines, which appear somewhat aggressive. As we published recently, the design of the H2H study (SEL-212 vs. Krystexxa) and the fact Krystexxa is being used as monotherapy may not fully resolve the investor debate around SEL-212’s commercial opportunity, even if results are positive. With that said, we remain encouraged after our discussion with management today in which it indicated securing a partnership for its ImmTOR platform remains a priority this year." (3/15/2019) 2. According to Zacks Investment Research, "Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States. " (1/10/2019) 3. Mizuho analysts commented, "We hosted a doc call on 10/29 to discuss SEL-212. Our consultant noted some of the main potential advantages of SEL-212 vs. the standard of care including; 1) Improved treatment regimen with fewer infusions (1x/month) vs. a proposed Krystexxa combo (2x/month + daily or weekly anti-proliferative agent) and 2) Superior safety profile. Our consultant believes SEL-212 is ready for phase 3 given considerable amounts of data generated to date on treatment regimen and dosing along with clear objective measurements showing tophi mitigation and lowering of uric acid levels in a majority of patients. She argued that had the stopping rules not been as stringent in the phase 2 trial, the results may have looked better." (11/5/2018) 4. Canaccord Genuity analysts commented, "We expect Selecta to present positive 5-dose Phase 2 combination data for SEL-212 in severe gout during 3Q18, and see significant upside for the stock. Selecta is likely to present data from multiple dosing cohorts, with up to n=20 patients from each cohort. We suspect focus will be on the 0.15 mg/kg SVP-rapamycin + 0.20 pegsiticase dose, but await upcoming data. We see little reason that SEL-212 will not reproduce data at 5 months similar to that seen at 3 months, where ~80% Serum Uric Acid control was shown." (7/11/2018) Has Selecta Biosciences been receiving favorable news coverage? News coverage about SELB stock has trended somewhat positive this week, InfoTrie reports. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Selecta Biosciences earned a coverage optimism score of 1.6 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. Are investors shorting Selecta Biosciences? Selecta Biosciences saw a increase in short interest in March. As of March 29th, there was short interest totalling 1,625,693 shares, an increase of 47.6% from the March 15th total of 1,101,211 shares. Based on an average daily trading volume, of 720,834 shares, the days-to-cover ratio is currently 2.3 days. Approximately 4.9% of the shares of the company are short sold. View Selecta Biosciences' Current Options Chain. Who are some of Selecta Biosciences' key competitors? Some companies that are related to Selecta Biosciences include Albireo Pharma (ALBO), Savara (SVRA), Innate Pharma (IPHYF), ImmunoGen (IMGN), Akorn (AKRX), Kezar Life Sciences (KZR), Sinovac Biotech (SVA), Geron (GERN), Keryx Biopharmaceuticals (KERX), Kindred Biosciences (KIN), XBiotech (XBIT), BioDelivery Sciences International (BDSI), Beyondspring (BYSI), Neptune Wellness Solutions (NEPT) and Insys Therapeutics (INSY). What other stocks do shareholders of Selecta Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Selecta Biosciences investors own include Catalyst Pharmaceuticals (CPRX), SCYNEXIS (SCYX), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Progenics Pharmaceuticals (PGNX), Viking Therapeutics (VKTX), Ardelyx (ARDX), Inovio Pharmaceuticals (INO), Melinta Therapeutics (MLNT) and Cara Therapeutics (CARA). Who are Selecta Biosciences' key executives? Selecta Biosciences' management team includes the folowing people: Dr. Omid C. Farokhzad, Co-Founder, Chairman & Member of the Scientific Advisory Board (Age 50)Dr. Lloyd Johnston, COO and Sr. VP of R&D (Age 51)Dr. John H. Leaman, Exec. Officer (Age 46)Dr. Werner Cautreels, Advisor (Age 67)Dr. Carsten Brunn, CEO, Pres & Director (Age 48) When did Selecta Biosciences IPO? (SELB) raised $64 million in an IPO on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers. How do I buy shares of Selecta Biosciences? Shares of SELB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Selecta Biosciences' stock price today? One share of SELB stock can currently be purchased for approximately $2.25. How big of a company is Selecta Biosciences? Selecta Biosciences has a market capitalization of $100.65 million and generates $900,000.00 in revenue each year. The company earns $-65,340,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis. Selecta Biosciences employs 39 workers across the globe. What is Selecta Biosciences' official website? The official website for Selecta Biosciences is http://www.selectabio.com. How can I contact Selecta Biosciences? Selecta Biosciences' mailing address is 480 Arsenal Way, Watertown MA, 02472. The company can be reached via phone at 617-923-1400 or via email at [email protected] MarketBeat Community Rating for Selecta Biosciences (NASDAQ SELB)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 197 (Vote Outperform)Underperform Votes: 210 (Vote Underperform)Total Votes: 407MarketBeat's community ratings are surveys of what our community members think about Selecta Biosciences and other stocks. Vote "Outperform" if you believe SELB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SELB will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/24/2019 by MarketBeat.com StaffFeatured Article: Why are gap-down stocks important?